Borean Pharma receives Notice of Allowance of HIV drug patent by U.S. Patent & Trademark Office

Aarhus, October 23 – Borean Pharma, ApS. the Danish biopharmaceutical and protein engineering company announced today that it has received a Notice of Allowance from the U.S. Patent & Trademark Office (USPTO) in connection with Borean’s patent application for Human Immunodeficiency Virus (HIV) fusion inhibitors for treating AIDS.

The USPTO has stated that it intends to grant patent protection which covers six proprietary drug candidates capable of inhibiting HIV from infecting human cells. The patent is expected to expire in 2025.

Borean’s HIV drug candidates are trimeric fusion proteins. These represent a next generation in HIV fusion inhibitors that are expected to combine greater patient safety and convenience with lower production and treatment costs.

"HIV remains one of the greatest challenges for medicine and this patent is therefore tremendously important to us," stated Dr. Johanna Holldack, CEO of Borean Pharma. "The acceptance of this patent is a significant milestone for Borean Pharma because it continues to solidify the positioning of our technologies and products."

- ends -

About Borean Pharma:

Borean Pharma was established with the objective to develop a new generation of pharmaceutical protein products. The company's competitive advantage lies in its proprietary technology, enabling it to develop a new generation of highly efficacious compounds and antibody analogues that can be produced in E. coli. The ease of production addresses a major shortcoming of monoclonal antibodies. Borean Pharma believes that it can unleash the true potential of biopharmaceuticals by providing efficacious and costeffective protein-based antibody analogues. The Company recently licensed its lead for atherosclerosis, Apo-AI, to Roche and, among other programmes, is also developing a TNF antagonist for Rheumatoid Arthritis. Borean was founded in 2001 as a spin-off from Aarhus University The firm has been backed by an investment syndicate consisting of Forbion Capital Partners, Aravis Venture, BankInvest Biomedical Venture, INCUBA Venture and NOVI. For further information please visit the website at: www.boreanpharma.com

Contact:

Borean Pharma
Dr. Johanna Holldack
CEO
t: +45 86 20 51 57
e: joh@boreanpharma.com

Northbank Communications
Dr. Douglas Pretsell
Account Director, Munich Bureau Chief
t: +49 (0)89 57 00 18 06
e: d.pretsell@northbankcommunications.com